Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).It received marketing approval in Canada and in the United States.As of 2007 it was the only GBCA approved at 1.0 molar concentrations.Gadobutrol is marketed by Bayer Schering Pharma as Gadovist and by Bayer HealthCare Pharmaceuticals as Gadavist.
This page contains content from the copyrighted Wikipedia article "Gadobutrol"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
